Comparison of East‐Asia and West‐Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness

Authors:
Publisher website
Google Scholar
Abstract
Surgical resection with lymphadenectomy and perioperative chemotherapy is the universal mainstay for curative treatment of gastric cancer (GC) patients with locoregional disease. However, GC survival remains asymmetric in West‐ and East‐world regions. We hypothesize that this asymmetry derives from differential clinical management. Therefore, we collected chemo‐naïve GC patients from Portugal and South Korea to explore specific immunophenotypic profiles related to disease aggressiveness and clinicopathological factors potentially explaining associated overall survival (OS) differences. Clinicopathological and survival data were collected from chemo‐naïve surgical cohorts from Portugal (West‐Europe cohort [WE‐C]; n = 170) and South Korea (East‐Asia cohort [EA‐C]; n = 367) and correlated with immunohistochemical expression profiles of E‐cadherin and CD44v6 obtained from consecutive tissue microarrays sections. Survival analysis revealed a subset of 12.4% of WE‐C patients, whose tumors concomitantly express E‐cadherin_abnormal and CD44v6_very high, displaying extremely poor OS, even at TNM stages I and II. These WE‐C stage‐I and ‐II patients tumors were particularly aggressive compared to all others, invading deeper into the gastric wall (P = .032) and more often permeating the vasculature (P = .018) and nerves (P = .009). A similar immunophenotypic profile was found in 11.9% of EA‐C patients, but unrelated to survival. Tumours, from stage‐I and ‐II EA‐C patients, that display both biomarkers, also permeated more lymphatic vessels (P = .003), promoting lymph node (LN) metastasis (P = .019), being diagnosed on average 8 years earlier and submitted to more extensive LN dissection than WE‐C. Concomitant E‐cadherin_abnormal/CD44v6_very‐high expression predicts aggressiveness and poor survival of stage‐I and ‐II GC submitted to conservative lymphadenectomy.
Funding Information
  • European Research Council (CoG 682810)
  • European Regional Development Fund (PTDC/BTM‐TEC/30164/2017, PTDC/BTM‐TEC/6706/2020)

This publication has 33 references indexed in Scilit: